1573 related articles for article (PubMed ID: 33510460)
21. Intermediate hepatocellular carcinoma: current treatments and future perspectives.
Dufour JF; Bargellini I; De Maria N; De Simone P; Goulis I; Marinho RT
Ann Oncol; 2013 Apr; 24 Suppl 2():ii24-9. PubMed ID: 23715940
[TBL] [Abstract][Full Text] [Related]
22. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies.
Marelli L; Stigliano R; Triantos C; Senzolo M; Cholongitas E; Davies N; Yu D; Meyer T; Patch DW; Burroughs AK
Cancer Treat Rev; 2006 Dec; 32(8):594-606. PubMed ID: 17045407
[TBL] [Abstract][Full Text] [Related]
23. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective.
Poon RT; Fan ST; Tsang FH; Wong J
Ann Surg; 2002 Apr; 235(4):466-86. PubMed ID: 11923602
[TBL] [Abstract][Full Text] [Related]
24. Present and future of new systemic therapies for early and intermediate stages of hepatocellular carcinoma.
Urquijo-Ponce JJ; Alventosa-Mateu C; Latorre-Sánchez M; Castelló-Miralles I; Diago M
World J Gastroenterol; 2024 May; 30(19):2512-2522. PubMed ID: 38817666
[TBL] [Abstract][Full Text] [Related]
25. New concepts in embolotherapy of HCC.
Pesapane F; Nezami N; Patella F; Geschwind JF
Med Oncol; 2017 Apr; 34(4):58. PubMed ID: 28299645
[TBL] [Abstract][Full Text] [Related]
26. Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma.
Mohr R; Jost-Brinkmann F; Özdirik B; Lambrecht J; Hammerich L; Loosen SH; Luedde T; Demir M; Tacke F; Roderburg C
Front Immunol; 2021; 12():652172. PubMed ID: 33859646
[TBL] [Abstract][Full Text] [Related]
27. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA
Trials; 2012 Aug; 13():144. PubMed ID: 22913492
[TBL] [Abstract][Full Text] [Related]
28. Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy.
Craciun L; de Wind R; Demetter P; Lucidi V; Bohlok A; Michiels S; Bouazza F; Vouche M; Tancredi I; Verset G; Garaud S; Naveaux C; Galdon MG; Gallo KW; Hendlisz A; Derijckere ID; Flamen P; Larsimont D; Donckier V
BMC Cancer; 2020 Feb; 20(1):135. PubMed ID: 32075608
[TBL] [Abstract][Full Text] [Related]
29. Advances in non-surgical management of primary liver cancer.
Chen X; Liu HP; Li M; Qiao L
World J Gastroenterol; 2014 Nov; 20(44):16630-8. PubMed ID: 25469032
[TBL] [Abstract][Full Text] [Related]
30. Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons.
Makary MS; Ramsell S; Miller E; Beal EW; Dowell JD
World J Gastroenterol; 2021 Nov; 27(43):7462-7479. PubMed ID: 34887643
[TBL] [Abstract][Full Text] [Related]
31. Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions.
Inchingolo R; Posa A; Mariappan M; Spiliopoulos S
World J Gastroenterol; 2019 Aug; 25(32):4614-4628. PubMed ID: 31528090
[TBL] [Abstract][Full Text] [Related]
32. Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis.
Majumdar A; Roccarina D; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011650. PubMed ID: 28351116
[TBL] [Abstract][Full Text] [Related]
33. Treatment of Primary Liver Tumors and Liver Metastases, Part 2: Non-Nuclear Medicine Techniques.
Cornelis FH; Solomon SB
J Nucl Med; 2018 Dec; 59(12):1801-1808. PubMed ID: 30361378
[TBL] [Abstract][Full Text] [Related]
34. Association of Addition of Ablative Therapy Following Transarterial Chemoembolization With Survival Rates in Patients With Hepatocellular Carcinoma.
English K; Brodin NP; Shankar V; Zhu S; Ohri N; Golowa YS; Cynamon J; Bellemare S; Kaubisch A; Kinkhabwala M; Kalnicki S; Garg MK; Guha C; Kabarriti R
JAMA Netw Open; 2020 Nov; 3(11):e2023942. PubMed ID: 33151315
[TBL] [Abstract][Full Text] [Related]
35. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma.
Song MJ; Bae SH; Lee JS; Lee SW; Song DS; You CR; Choi JY; Yoon SK
Korean J Intern Med; 2016 Mar; 31(2):242-52. PubMed ID: 26874512
[TBL] [Abstract][Full Text] [Related]
36. Prospective evaluation of patients with early-/intermediate-stage hepatocellular carcinoma with disease progression following arterial locoregional therapy: candidacy for systemic treatment or clinical trials.
Memon K; Kulik L; Lewandowski RJ; Gupta R; Ryu RK; Miller FH; Vouche M; Atassi R; Ganger D; Mulcahy MF; Salem R
J Vasc Interv Radiol; 2013 Aug; 24(8):1189-1197.e2. PubMed ID: 23474327
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant therapy for hepatocellular carcinoma: current situation and prospect.
Wang Z; Zhang G; Wu J; Jia M
Drug Discov Ther; 2013 Aug; 7(4):137-43. PubMed ID: 24071575
[TBL] [Abstract][Full Text] [Related]
38. Neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: where do we stand?
Fujiki M; Aucejo F; Choi M; Kim R
World J Gastroenterol; 2014 May; 20(18):5308-19. PubMed ID: 24833861
[TBL] [Abstract][Full Text] [Related]
39. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.
Han K; Kim JH
World J Gastroenterol; 2015 Sep; 21(36):10327-35. PubMed ID: 26420959
[TBL] [Abstract][Full Text] [Related]
40. Transarterial chemoembolization, ablation, tyrosine kinase inhibitors, and immunotherapy (TATI): A novel treatment for patients with advanced hepatocellular carcinoma.
Meng M; Li W; Yang X; Huang G; Wei Z; Ni Y; Han X; Wang J; Ye X
J Cancer Res Ther; 2020; 16(2):327-334. PubMed ID: 32474520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
